An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice

Sponsor
Hoffmann-La Roche
Study ID
NCT01474291
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — BIOLOGICAL
    Tocilizumab administered according to prescribing information and normal clinical practice.

Study Details

This prospective, multi-center, observational study will evaluate factors influencing the use of tocilizumab (RoActemra/Actemra) as monotherapy in rheumatoid arthritis patients in real life setting. Data will be collected from participants for 12 months following initiation of tocilizumab treatment.

Key Dates

Start date
Jan 31, 2012
Status verified
Sep 2016
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014

Study Design

Enrollment
608 participants (actual)

Arms

  • Arm: Tocilizumab
    Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.

Primary Outcome Measure

Number of Participants Assigned Tocilizumab Monotherapy Versus Tocilizumab as Part of Combination Therapy at Study Inclusion [ Time Frame: Day 1 ]

Related Studies